TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00330629

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Treatment
Description: Participants in this condition will receive the standard behavioral treatment (SBT) described above. Food tastings will be held at the sessions and will focus on fat modified food products.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Treatment
Description: Participants in this condition will receive the standard behavioral treatment (SBT) described above. Food tastings will be held at the sessions and will focus on fat modified food products.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SBT+LOV
Description: The focus will be on the elimination of meat products as a means to reduce fat intake.
Study: NCT03778255

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: 1. Injecting carbon nanoparticles (CNP)\[Not Equipped with near-infrared fluorescent vascular imager\] or CNP combining Indocyanine Green(ICG)\[Equipped with near-infrared fluorescent vascular imager\].~2. Identifying and removing sentinel lymph nodes.~3. Staining all nodes using hematoxylin-eosin staining.
Study: NCT00971646

Intervention type: OTHER
Intervention: Micturition diary
Description: On the micturition diary patients are asked to note every void and drink. With every void they are asked to estimate their bladder volume and grade their degree of desire to void.

Intervention type: OTHER
Intervention: Micturition diary
Description: On the micturition diary patients are asked to note every void and drink. With every void they are asked to estimate their bladder volume and grade their degree of desire to void.

Intervention type: OTHER
Intervention: Hospital Anxiety and Depression scale
Description: This questionnaire is designed to screen for the presence of a mood disorder.

Intervention type: OTHER
Intervention: Hospital Anxiety and Depression scale
Description: This questionnaire is designed to screen for the presence of a mood disorder.

Intervention type: OTHER
Intervention: EuroQol-5D
Description: This questionnaire grades the health condition of the subject.

Intervention type: OTHER
Intervention: EuroQol-5D
Description: This questionnaire grades the health condition of the subject.

Intervention type: OTHER
Intervention: Self-consciousness questionnaire
Description: The questions tap cognitive, emotional, and physical appearance aspects of directing their attention to the self.

Intervention type: OTHER
Intervention: Self-consciousness questionnaire
Description: The questions tap cognitive, emotional, and physical appearance aspects of directing their attention to the self.
Study: NCT03176966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Patients will take 400 IU vitamin E nightly for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Patients will take 400 IU vitamin E nightly for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole
Description: Patients will take 0.5mg ropinirole nightly for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole
Description: Patients will take 0.5mg ropinirole nightly for 3 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle cramp survey
Description: Patients will complete a survey of muscle cramp frequency and severity at baseline, 3 months, and 6 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle cramp survey
Description: Patients will complete a survey of muscle cramp frequency and severity at baseline, 3 months, and 6 months.
Study: NCT04125823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game-based physical activity training
Description: Based on the physical levels of the patients, appropriate games will be selected and video game based physical activity training will be started. Video games will be played with Xbox One with a motion sensor (Microsoft) and a 52'' Liquid Crystal Display. Depending on the prognosis of the patients, the grades and types of games will be changed.~Sessions will be performed by a physiotherapist for 45 minutes once a day during the hospital stay.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy program
Description: A conventional physiotherapy program including balance, upper extremity, and core stabilization exercises will be implemented.~Sessions will be performed by a physiotherapist for 45 minutes once a day during the hospital stay.
Study: NCT03988751

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ambulation
Description: Variation in ambulatory intensity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ambulation
Description: Variation in ambulatory intensity.
Study: NCT01853228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase1 and Phase 2: decitabine
Description: 20 mg/m2 administered by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of 28-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1: cytarabine
Description: 1 g/m2, 2 g/m2, and 1.5 g/m2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle) for the determination of the maximum tolerated dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2: cytarabine
Description: Phase 1 maximum tolerated dose administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle)
Study: NCT01223911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0151-0000-0000
Description: Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
Study: NCT01635361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Medicine Service
Description: The New Medicine Service is an intervention where patients prescribed a new medicine receive followup consultations with the pharmacist 7-14 days and 14-21 days after receiving the new prescription item
Study: NCT01862211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: A blood sampling will be performed for the genetic analysis and the measurement of serum IL-8.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: A blood sampling will be performed for the genetic analysis and the measurement of serum IL-8.
Study: NCT00574977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinia virus (vvDD-CDSR)
Description: Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be \< 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u.
Study: NCT01769118

Intervention type: DRUG
Intervention: Caffeine
Description: Caffeine will be given according to departmental protocol
Study: NCT04561609

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous CO2 application
Description: Patients lie on examination tables. Lower extremities of the patients are isolated in a therapeutic wrap (single use, low-density, made from biocompatible polyethylene), sealed at the waist. After this, air is first pumped out of the therapeutic wrap, then the wrap was filled with 99.9% CO2 gas. The therapy lasts for 45 minutes.~Each patient from the study group will receive CO2 therapies - four weeks (meaning 20 CO2 therapies that were performed on workdays only).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Each patient from control group will have therapeutic wrap filled with air instead of CO2. Patients from control group will also receive 20 therapies (4 weeks on workdays only), that will also last 45 minutes.
Study: NCT02405637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simulated amniotic fluid 20cc/kg/day enterally
Description: simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: distilled water
Description: distilled water 20 ml/kg/day for maximum of 7 days.
Study: NCT01693237

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group psychotherapy
Description: 20 sessions of systemic and narrative group therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group psychotherapy with feedback
Description: 20 sessions of systemic and narrative group therapy
Study: NCT03967574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: The tDCS anode was applied on the primary motor cortex area responsible for the control of the rotator cuff, as determined using transcranial magnetic stimulation and surface electromyography. The cathode was applied on the contralateral forehead, just above the eyebrow. The electrodes were soaked in saline solution to improve conductivity and the montage was secured with rubber bands and adhesive tape.~The tDCS device (Soterix Medical 1x1 tDCS device) was then gradually turned to an intensity of 2mA. This stimulation was continued for a total of 20 minutes, after which it was gradually stopped.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: The tDCS anode was applied on the primary motor cortex area responsible for the control of the rotator cuff, as determined using transcranial magnetic stimulation and surface electromyography. The cathode was applied on the contralateral forehead, just above the eyebrow. The electrodes were soaked in saline solution to improve conductivity and the montage was secured with rubber bands and adhesive tape.~The tDCS device (Soterix Medical 1x1 tDCS device) was then gradually turned to an intensity of 2mA. This stimulation was continued for a total of 20 minutes, after which it was gradually stopped.
Study: NCT01032343

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 PUFA
Description: One capsule (4g omega-3 PUFA) daily for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gelatine
Description: One capsule daily for 3 months
Study: NCT00785447

Intervention type: OTHER
Group type: OTHER
Intervention: Mouth-to-mouth or mouth-to-nose breathing
Description: Patients undergoing elective surgery under general anesthesia will be given mouth-to-mouth and mouth-to-nose breaths. The respiration process will be measured and recorded by the help of elastic bands put around the chest and abdomen. The efficiency of the breathing methods will be evaluated.
Study: NCT02243826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50:50 mixture of nitrous oxide/oxygen

Intervention type: DRUG
Group type: OTHER
Intervention: 50:50 mixture of nitrous oxide/oxygen
Study: NCT04555733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: Lemborexant oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: Lemborexant oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: Lemborexant oral tablets.
Study: NCT02691377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture group
Description: Acupoints include 11 on the head, two on the upper extremities, and two on the lower extremities. Before performing acupuncture, a small pad will be pasted on each acupoint. All the needles will insert the acupoints through these pads. Then, they will be twirled, lifted and thrust three times to elicit the Deqi sensation. Each session will last 30 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture group
Description: The same acupoints with acupuncture group are selected.A placebo needle with a blunt tip will be used to perform sham acupuncture. They will only insert the pad and no skin penetration. The same procedure with acupuncture group will be performed.
Study: NCT03987880

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4.0 mm treatment
Description: PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3.5 mm treatment
Description: PiXL treatment with UV irradiation in a central 3.5-mm ring-shaped zone of the cornea.
Study: NCT03614585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12 weeks of High-intensity Interval Training
Description: Cardiovascular exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12 weeks of Moderate-Intensity Continuous Training
Description: Cardiovascular exercise
Study: NCT02178436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT02246036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APD probe
Description: The probe will be placed in the patient with an endoscopic procedure by a gastroenterologist (standard procedure for post-pyloric tubes placement).
Study: NCT02142621

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transpyloric feeding

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gastric feeding
Study: NCT00871000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix Polio™ 711866
Description: Single dose, intramuscular administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix Tetra TM 208136
Description: Single dose, subcutaneously.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Priorix Tetra TM 208136
Description: Single dose, subcutaneously.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetravac TM
Description: Single dose, intramuscular administration.
Study: NCT02532946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedsider.org counseling
Description: Contraceptive counseling was done while women kept the computer/tablet throughout their visit to facilitate discussion of website information with their providers.
Study: NCT02168439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study: NCT02596984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin
Description: Either preemptive, empirical or curative prescription of Caspofungin by one of the ICUs' attending physician. Caspofungin will be administered according to the international recommendation
Study: NCT02178436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00574977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinia virus (vvDD-CDSR)
Description: Eligible subjects will receive 1 infusion of vvDD-CDSR.~Cohort 1: 3 x 10e8 p.f.u; Cohort 2: 1 x 10e9 p.f.u.; Cohort 3: 3 x 10e9 p.f.u.
Study: NCT02267577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sphygmo: Automatic Blood Pressure Monitor
Description: A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE Dinamap ProCare Automatic Blood Pressure Monitor
Description: This commercially available gold standard blood pressure monitor will be used as a control to assess the accuracy of the Sphygmo device.
Study: NCT04710589

Intervention type: RADIATION
Intervention: CTV
Description: According to the clinical conditions of the patients, they will be assigned to two groups based on the doctor's recommendations and their own wishes
Study: NCT01803165

Intervention type: PROCEDURE
Intervention: Single shot femoral and sciatic nerve block
Description: Ultrasound will be performed with a linear 10- to 13-Megahertz probe while performing the nerve block. Standard American Society of Anesthesiology monitors will be applied and the patient sedated at the discretion of the anesthetic team. Complications such as vascular puncture, pain on injection, or systemic toxicity will be recorded. A perineural dosing regimen for the regional blocks will be as follows: (femoral block) 20cc of 0.5% ropivicaine and (sub-gluteal posterior sciatic block) 20cc of 0.2% ropivicaine. Epinephrine will be withheld from the local anesthetic in order to prevent the potential of further ischemic complications.
Study: NCT02172222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Study: NCT02718677

Intervention type: DRUG
Intervention: Refacto AF
Description: Observational - Non-Interventional Study
Study: NCT02967120

Intervention type: OTHER
Intervention: no intervention
Study: NCT01709799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will do physical activity that raises heart rate to a target heart rate (THR)zone which is pre-calculated using the Karvonen Formula:~(THR={(max. heart rate- rest heart rate) x %intensity} + resting heart rate~Participants begin exercise regimen starting at 50% THR for intensity and gradually increase by 5% up to a maximum of 75% THR.~Activity duration begins at 10 mins./day and increases 5 mins. every week following to a maximum of 40 mins. Polar Heart Rate monitors are used to measure THR and save resulting data.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exergames
Description: Participants experience Wii Video Games in a standardized format, beginning with 15 mins of seated play per day on week one, and then increasing 5 mins./week on each week following up to a maximum of 40mins. of play.~Participants are made aware of the Target Heart Rate Zone for the week, but are not required to reach that zone during play. The THR is calculated by the Karvonen Formula:~THR={(max. heart rate- rest heart rate) x %intensity} + resting heart rate~Polar Heart Rate monitors are used to measure THR and save resulting data.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Posit Science INSIGHT program games are used for all cognitive training. Participants are exposed to (2) forty minute game sessions per day, for the cognitive training weeks #4,8,12,16.~INSIGHT Assessments are done at baseline, the start of each training week and at week 28.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Posit Science INSIGHT program games are used for all cognitive training. Participants are exposed to (2) forty minute game sessions per day, for the cognitive training weeks #4,8,12,16.~INSIGHT Assessments are done at baseline, the start of each training week and at week 28.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Posit Science INSIGHT program games are used for all cognitive training. Participants are exposed to (2) forty minute game sessions per day, for the cognitive training weeks #4,8,12,16.~INSIGHT Assessments are done at baseline, the start of each training week and at week 28.
Study: NCT02740153

Intervention type: OTHER
Intervention: No Intervention Given

Intervention type: OTHER
Intervention: No Intervention Given
Study: NCT01586663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Serial night time position splint
Description: This group will use a serial night time position splint, adjusted monthly, during three months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug treatment
Description: This patients will keep there drug treatment and will receive their splints on the end of the study.
Study: NCT00318201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Study: NCT02213757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin vaginal estrogen cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal cream
Description: Inactive vaginal cream manufactured to mimic Premarin vaginal cream
Study: NCT04050904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExpHeart
Description: ExpHeart is composed of an Information System (web application) and an algorithm, the Expert System, embedded on the Information System. The Information System is a cyber-securised web application and the Expert System uses a proprietary therapeutic algorithm to optimize pharmacological HF treatment. The Expert System is based on the analysis of a continuously updated clinical database integrating the patient's electronic medical record (managed by the Information System). The Expert System will generate prescription recommendations directed to the treating investigator through the Information System.
Study: NCT04356001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket preservation
Description: 'One-Piece' autologous tuberosity graft combining hard and soft tissue, harvested from the maxillary tuberosity, placed in extraction sockets.
Study: NCT00003930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study: NCT06445335

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FibroScan
Description: Performance of a FibroScan measurement.
Study: NCT00003930

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00756925

Intervention type: DRUG
Intervention: Acthrel
Description: 1 ug/kg, i.v., 1 minute

Intervention type: DRUG
Intervention: Acthrel
Description: 1 ug/kg, i.v., 1 minute